Are there any promising new treatments for chronic dry eye relief that have recently come on the market and might be covered by standard flexible spending accounts?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Are there any promising new treatments for chronic dry eye relief that have recently come on the market and might be covered by standard flexible spending accounts?
3 real searches · 1 real-search pass
new FDA approved chronic dry eye treatments 2025 2026 Tryptyr Vevye Miebo reproxalap statusGoogle ↗
OBSERVED
FSA eligible dry eye eye drops prescription over the counter IRS medical expenses 2026 HSA FSAGoogle ↗
OBSERVED
Tryptyr acoltremon FDA approval prescribing information dry eye 2025 efficacyGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
new FDA approved chronic dry eye treatments 2025 2026 Tryptyr Vevye Miebo reproxalap status Google ↗
FSA eligible dry eye eye drops prescription over the counter IRS medical expenses 2026 HSA FSA Google ↗
Tryptyr acoltremon FDA approval prescribing information dry eye 2025 efficacy Google ↗
- Drug Trials Snapshot: TRYPTYR · fda.gov
- These highlights do not include all the information needed to use TRYPTYR® safely and effectively. See full prescribing information for TRYPTYR . TRYPTYR (acoltremon ophthalmic solution) 0.003%, for topical ophthalmic use Initial U.S. Approval: 2025 · dailymed.nlm.nih.gov
- Drug Trials Snapshot: MIEBO · fda.gov
- label · accessdata.fda.gov
- These highlights do not include all the information needed to use VEVYE ®safely and effectively. See full prescribing information for VEVYE. VEVYE (cyclosporine ophthalmic solution) 0.1%, for topical ophthalmic use Initial U.S. Approval: 1983 · dailymed.nlm.nih.gov
- Improved Dry Eye Drugs for 2025 and Beyond · aao.org
- Publication 969 (2025), Health Savings Accounts and Other Tax-Favored Health Plans · irs.gov
- Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease · ir.aldeyra.com
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
new FDA approved chronic dry eye treatments 2025 2026 Tryptyr Vevye Miebo reproxalap status OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FSA eligible dry eye eye drops prescription over the counter IRS medical expenses 2026 HSA FSA OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
Tryptyr acoltremon FDA approval prescribing information dry eye 2025 efficacy OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |